RT-treated patients with low ARID1A expression from other tumor entities, such as skin cutaneous melanoma (SKCM), thyroid carcinoma (THCA), and glioblastoma multiforme (GBM), displayed higher expression of CXCL10, IL-6 and CXCL9. This evidence concerns the gene IL6 and neoplasm.